

Andrea Terron

Education

- | | |
|-------------|---|
| 1984 | Degree in Veterinary Medicine, University of Parma (Italy), 110/110 with laudem |
| 1988 | Diplome Universitaire du Pathologique Toxicologique et Experimentale. Ecole de Medicine Veterinaire d'Alfort, Paris (France) |
| 1996 | Diploma Royal College Pathology in Toxicology, Toxicological Pathology and Comparative Pathology |
| 1998 | Membership Royal College Pathology in Toxicology, Toxicological Pathology and Comparative Pathology (Board Certificate) |
| 2004 | Fellow of the Royal College of Pathologists in Toxicology |

Language

Italian (mother tongue)
English (fluent)
French (satisfactory)

Employments:

Position Title: Pathologist

Company name, Country: Glaxo Wellcome, Department of Safety Assessment (Italy)
Year from: 1986-2000

Position Title: Director of Pathology

Company name, Country: Pharmacia, Nerviano, Milano, Italy
Year from -2000-2004

Position Title: Director of Toxicology

Company name, Country: GSK, Verona, Italy
Year from -2004-2006

Position Title: Director of Non Clinical Safety Project

Company name, Country: GSK Ware, UK
Year from -2006-2011

Position Title: Senior Toxicology Scientific Officer

Company name, Country: European Food Safety Authority (EFSA), Parma, Italy
Year from May 2011- May 2012

Position Title: Director of Toxicology

Company name: Novartis Vaccines & Diagnostics
June 2012-march 2013

Position Title: Senior Toxicology Scientific Officer (Contract agent)
Company name, Country: European Food Safety Authority (EFSA), Parma, Italy
Year from March 2013- current

Others:

- **Teaching at : Master regolatorio, Universita' di Camerino.**
- **Teaching at: Facolta di scienze farmacologiche, scuola di risk assessment, Universita' di Milano.**

Publications AND POSTERS

Murari R., Terron A., Faccincani F., Colosi A.
USSL n° 25 Regione Veneto Centro Macellazione Verona: I Bolli e la Carne.
La Carne, 6, 1985

Faccincani F., Murari R., Olivi F., Terron A.
Il Computer nel Macello.
La Carne, 1, 1986

Terron A., Olivi F., Marini M., Barbisio P.
Gestione computerizzata dei dati epidemiologici del macello.
La Carne, 1988

Cristofori P., Terron A., Micheli D., Bertolini G., Carpi C.
Vascular protection of Lacidipine in Salt-Loaded Dahl-s rats at non sustained antihypertensive doses.
Journal of Cardiovascular Pharmacology, 17 (suppl. 4), 1991

Carpi C., Cristofori P., Terron A., Micheli D.
Vascular Protection of Lacipidine at no antihypertensive doses.
XI International Congress of Pharmacology, Amsterdam, 1/7.07.1990

Chiamulera C., Cristofori P., Costa S., Spagnolo D., Terron A., Reggiani A.
Rodents models of ischaemia induced neurodegeneration: an approach to study potential neuroprotective agents.
Poster, Congresso Int. di Parma della Soc. Intern. di Neurotoxicology. Parma Luglio 1991
Cristofori P., Terron A., Buglioli M., Bertolini G.
Characterization of brain lesions by histological and immunohistochemical methods in spontaneously hypertensive Dahl-s rats.
Poster presentato all'Eurotox 1991, Maastricht, NL

Cristofori P., Terron A., Marrelli M., Moretti U., Pasqualicchio M., Velo GP., Milanino R.
Copper supplementation in the rat: preliminary observations on the clinical, hematological and histopathological profile.
Poster presentato al Congresso Internazionale della International Society on Inflammation. Verona, maggio 1991

Micheli D., Terron A., Cristofori P.

Lacidipine protection of cerebral and ocular vascular hyperpermeability: microscopic aspects.

Poster presentato al Congresso Internazionale sull'ipertensione e Ca-antagonisti.
Houston, USA, settembre 1991

Gaviraghi G., Micheli D., Terron A., Cristofori P.

Lacidipine: Prevention of vascular damage induced by hypertension.

Journ. of Cardiovascular Pharmacology, Vol. 18, Suppl. 11, 1991, Raven Press.

Cristofori P., Terron A., Spagnolo D.

Caratterizzazione istologica ed immunoistochimica di un modello sperimentale di neurodegenerazione cronica.

Bioinformazione Anno III, 3, nov. 1991

Cristofori P., Terron A., Marrella M., Moretti U., Pasqualicchio M., Velo GP., Milanino R.

Copper supplementation in the rat: preliminary observations and clinical, hematological and histopathological profile. Agent Actions, Special Conference Issue, 1992

Cristofori P., Gerrard PA., Melotto S., Reggiani A., Terron A.

Histological characterisation of neuronal damage induced by chronic intraventricular infusion of Quinolinic Acid. Toxicology letters, Vol. 61, Suppl. 1, 1992

Cristofori P., Dal Negro G., Dorigatti R., Terron A.

Determination of protein concentration in urine by two different methods and their applicability in toxicity studies. Toxicology letters, Vol. 61, Suppl. 1, 1992

Dal Negro G., Cristofori P., Spagnolo D., Tarter G., Pastorino A., Micheli D., Magro A., Bonato M., Terron A.

The fat-fed hamster as a model of atherosclerosis

5th Congress of International Society of Animal Clinical Biochemistry. Parma 2-6.9.1992

Micheli D., Gaviraghi G., Terron A., Cristofori P.

Vascular protective properties of lacidipine in experimental hypertension.

Pharmacologic Research, 26 (suppl 1) 158, 1992

Chiamulera C., Terron A., Reggiani A., Cristofori P.

Qualitative and quantitative analysis of the progressive cerebral damage after middle cerebral artery occlusion in mice.

Brain Research, 606 (1993) 251-258

Cristofori P., Sbarbati A., Accordini C., Terron A., Micheli D.

Protective action of lacidipine in cardiac hypertrophy of the spontaneously hypertensive stroke-prone rat: an ultrastructural study.

J. Submicrosc. Cytol., 26 (3), 331-340, 1994

Cristofori P., Micheli D., Terron A., Gaviraghi G.

Lacidipine: Experimental Evidence of Vasculoprotective Properties.

Journal of Cardiovascular Pharmacology, 23 (suppl. 5): S90-S93, 1994

Draghetti MT., Terron A., Perazzolo M.

Subcutaneous Administration of High Volume of 5% Dextrose Solution in Pregnant Han Wistar Rat Embryotoxicity Studies.

24th European Teratology Society Conference, 2-5 Sept 1996, Roma

Terron A., Cristofori P., Chiamulera C., Spagnolo D.
Histological and immunohistochemical characterization of neurodegenerative model with special reference to Huntington's disease.
15th meeting of the European Society of Veterinary Pathology.
16-19 September 1997 - Alghero - Italy

Terron A., Dorigatti R., Cristofori P., Roberts K.L.
Investigation of acute intravenous effects of Polyvinyl-Pyrrolidone.
15th meeting of the European Society of Veterinary Pathology.
16-19 September 1997 - Alghero - Italy

Bordi F., Terron A.
The neuroprotective glycine antagonist GV150526 does not produce neurovacuolation in rat brain.
Journal of European Pharmacology, November 1999

Bunemann B., Zantedeschi V., Terron A., Chiamulera C.
Chronic nicotine induce changes in brain structures; effects on brain neurofilaments.
Poster presented to the First International Congress of Smoking Cessation
Canaries Islands, February 1999

Bunemann B., Zantedeschi V., Terron A., Chiamulera C., Merlo Pich E.
Chronic nicotine induces changes in brain structures; effects on brain neurofilaments.
Presented at the International Symposium on Nicotine receptor (Venezia September 99)

Della Torre P., Podestà A., Imondi A.R., Moneta D., Sammartini U., Arrigoni C., Terron A., Brughera M.
PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxicity potential.
Cancer Chemoter. Pharmacol., (2001) 47: 355-360

B.Bunemann, A.Terron, V.Zantedeschi, E. Merlo Pich, C.Chiamulera
Chronic nicotine treatment decreases neurofilament immunoreactivity in the rat ventral tegmental area
European journal of pharmacology 393, (2000) 249-253

A.Sbarbati, B.Bunemann, P.Cristofori, A.Terron, C.Chiamulera, F.Merigo, D.Benati, P.Bernardi, F.Osculati
Chronic nicotine treatment changes the axonal distribution of 68kD neurofilaments in the rat ventral tegmental area
European Journal of Neuroscience 2002

A.Terron et al.
Comparative evaluation by histological and magnetic resonance imaging of subcutaneous xenograft tumor models in the mouse.
Poster presented at the 20th mtg of the European Society of Veterinary Pathology.Torino, September 2002

A.Terron et al.
Drug induced pathological lesions in mucus secreting cells in the jejunum of the Beagle dog

Poster presented at the 20th mtg of the European Society of Veterinary Pathology.Torino, September 2002.

A.Terron et al.

Ex vivo analysis to study the mode of action of a CDK2 inhibitor.

Poster presented at the 93rd annual mtg of the American association for Cancer Research. San Francisco US, March 2002

A.Terron et al.

Evaluation of the efficacy of an anti-angiogenesis compound SU6668 in a xenograft tumor model by Dynamic Contrast enhanced-MRI (DCE-MRI)

Poster presented at the 93rd annual mtg of the American association for Cancer Research. San Francisco US, March 2002

A.Terron et al.

Ultrastructural alterations in rat's exocrine pancreas. Detection of rapid onset using TEM characterization.

Poster presented at the International Congress on Electron Microscopy. Durban, South Africa 2002

P.Marzola, P. Farace, L.Calderan, C.Crescimanno, E.Lunati, E.Nicolato, D.Benati, A.Degrassi, A.Terron, J.Klapwijk, E.Pesenti, A.Sbarbati, F.Osculati

In vivo mapping of fractional plasma volume and endothelial transfer coefficient in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure.

Int.J.Cancer 104, 462-468 (2003)

P.Marzola, P. Farace, L.Calderan, C.Crescimanno, E.Lunati, E.Nicolato, D.Benati, A.Degrassi, A.Terron, J.Klapwijk, E.Pesenti, A.Sbarbati, F.Osculati

In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model

Clinical Cancer Research Vol 10, 739-750, January 15, 2004.

A.M. Giusti A. Terron

Changes in drug formulation can induce new target organ toxicity: safety assessment of renal toxicity of a new chemical entity dissolved in SBE7 Beta cyclodextrin

Poster presented at the ESTP Congress 2004

Terron et al.

Validation of a new method for troponin I detection in Han Wistar (HW) rats

Poster presented at the European Society of Veterinary Pathology, congress 2004

AM Giusti, A. Terron, S. Belluco, E. Scanziani, MLCarcangiu

Ovarian epithelial trophoblastic tumor in a Cynomolgus Monkey

Vet Path 42:223-226 (2005)

Marzola, A Degrassi, L Calderan, P Farace, E Nicolato, C Crescimanno, M Sandri, A. Giusti, E Pesenti, A. Terron, A. Sbarbati, F. Osculati.

Early Antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

Clinical Cancer Research 2005; 11 (6) August 15, 2005

Patina, Terron et al: Non clinical safety evaluation of Sunitinib, a potent inhibitor of VEGF, PDGF, KIT,FLT3 and RET receptors. Toxicol Pathol. 2008 Dec;36(7):905-16. doi: 10.1177/0192623308326151. Epub 2008 Nov 3.

Buss NA, Gavins FN, Cover PO, Terron A, Buckingham JC FASEB J. 2015 Jul;29(7):2930-42. doi: 10.1096/fj.14-268375. Epub 2015 Mar 27.Targeting the annexin 1-formyl peptide receptor 2/ALX pathway affords protection against bacterial LPS-induced pathologic changes in the murine adrenal cortex.

Fritsche E, Crofton KM, Hernandez AF, Hougaard Bennekou S, Leist M, Bal-Price A, Reaves E, Wilks MF, Terron A, Solecki R, Gourmelon A.
OECD/EFSA workshop on developmental neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes. ALTEX. 2017;34(2):311-315. doi: 10.14573/altex.1701171. PubMed ID: 28407175.

Olavi Pelkonen Andrea Terron Antonio F. Hernandez Pablo Menendez Susanne Hougaard Bennekou. Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research. Archives of toxicology. 2017. Arch.Toxicol.91:2763-2780 doi:10.1007/s00204-017-1986-x.

Marcel Liest, Andrea Terron et al. 2017. Adverse Outcome Pathway: opportunities, limitations and open question. ArchToxicol. DOI.10.1007/s002014-017-2045-3

Terron A. and al. Recommendation on test readiness criteria for new approach methods in toxicology: exemplified for developmental neurotoxicity. ALTEX 35(3), 2018.

Terron A. et al. Consensus statement on need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes. 2018.Toxicology and Applied Pharmacology. <https://doi.org/10.2016/j.taap.2018.02.004>.

Terron A. Hougaard S. Towards a regulatory use of alternative developmental neurotoxicity testing. 2018. <https://doi.org/10.2016/j.taap.2018.02.002>

Terron A. et al. International regulatory and scientific effort for improved developmental neurotoxicity testing. 2018. Toxicology Sciences.

Terron A. et al. Integration of epidemiological findings with mechanistic evidence in regulatory pesticide risk assessment: EFSA experiences. Arch Toxicol. 2019 Jun;93(6):1779-1788. doi: 10.1007/s00204-019-02467-w. Epub 2019 May 3.

Terron A. et al. An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. Arch Toxicol. 2018; 92(1): 41–82 Published online 2017 Dec 5. doi: 10.1007/s00204-017-2133-4 .

Terron et al. Template for the Description of Cell-Based Toxicological Test Methods to Allow Evaluation and Regulatory Use of the Data. 2019. ALTEX 36(4), 682-699. doi:10.14573/altex.1909271.

Terron A et al. 2021.Toward a Better Testing Paradigm for Developmental Neurotoxicity: OECD Efforts and Regulatory Considerations Biology, 10(2), 86; <https://doi.org/10.3390/biology1002008>.

Terron A. et al. The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells. Hematologica, in press.

INVITATION TO PUBLIC EVENTS AND SCIENTIFIC CONFERENCES

Terron A., Lanzoni A., Spagnolo D., Zantedeschi V.,
The role of morphologic evaluation in detecting neurotoxicity: strategy and
Examples. Presented as oral communication at the Società Italiana di Tossicologia
Bologna Febbraio 2000

Fornasier M., Ferraro A., Sartori M., Cunago L., Turrini G., Terron A., Dorigatti R.
A model of intestinal absorption and hepatic first-pass effect in the anaesthetized rat.
Presented as oral communication at the Società Italiana di Tossicologia.
Bologna Febbraio 2000

Ciabini, Terron, Galassi, Raimondo: disegno, utilizzo e predittività degli studi preliminari in
specie non rodentrici nello sviluppo tossicologico dei farmaci. Oral communication XIV congresso
nazionale della società italiana di tossicologia 2004

Terron, Moccia, Raimondo: uso e limiti della NOAEL nella valutazione del rischio negli studi
preclinici durante lo sviluppo dei farmaci. Oral communication XIV congresso nazionale della
società italiana di tossicologia.

Costa, Terron, Dorigatti, Raimondo: approccio sistematico per la valutazione dei campioni
tossicocinetici negli animali di controllo. Poster presentato al XIV congresso nazionale della
società italiana di tossicologia.

School of Chemistry. Urbino, September 2009. Invited speaker: Preclinical safety assessment in
drug discovery.

DIA, Annual meeting in Monaco, March 2010: Invited speaker on preclinical management of
convulsion related risk.

BSTP training module on Cancerogenesis; March 2010: Invited speaker.

Flavouring annual meeting. February 2012, London UK; invited speaker.

Eurotox 2014: Invited speaker.

Eurotox 2016: Invited speaker,

SOT 2016: Invited speaker,

ESTIV 2016; invited speaker.

International Conference of Toxicology 2016: Invited speaker.

German Society of Clinical Pharmacology and Toxicology 2016: Invited speaker.

ecopa SSCT Workshop 2017. Invited speaker.

Eurotox 2017: invited speaker.

Eurotox 2018: invited speaker.

SITOX 2018: Invited speaker.

EPAA 2019: invited speaker.

Eurotox 2019, invited speaker.

Sitox 2020, invited speaker.

Sitox 2021, invited speaker.

European Commission; Training on endocrine disrupters: 2 editions in 2019, 1 edition in 2020, 1 edition in 2021 (teacher)

MEMBERSHIP

1. British Society of Toxicological Pathology
2. Royal College of Pathologists